4/A: Atea Pharmaceuticals Director Franklin M. Berger Corrects Stock Acquisition Filing

Atea Pharmaceuticals director Franklin M. Berger amended a previous filing to correct a transaction code error, confirming the acquisition of 25,000 shares of common stock.

Summary

• Franklin M. Berger, a director at Atea Pharmaceuticals, filed an amendment to a previous Form 4 to correct a transaction code error.
• The original filing incorrectly indicated a disposal of shares, but the amendment clarifies that the transactions were acquisitions.
• Mr. Berger acquired 15,000 shares of common stock on January 15, 2025, at a weighted average price of $3.1923 per share.
• He also acquired an additional 10,000 shares on January 16, 2025, at a weighted average price of $3.3614 per share.
• The total number of shares beneficially owned by Mr. Berger after these transactions is 476,897.

Sentiment

Score: 7

Explanation: The document corrects an error in a previous filing, which is a positive for transparency. The share purchases by the director are a positive sign, but the overall impact is neutral.

Positives

• The amendment clarifies the nature of the transactions, ensuring accurate reporting of insider activity.
• The director's acquisition of shares could be seen as a positive signal of confidence in the company.

Risks

• The initial error in the filing could raise questions about the accuracy of other filings, although it was corrected quickly.
• While the share purchases are a positive sign, the market may react to the correction itself.

Industry Context

This filing is a routine disclosure of insider trading activity, which is common in the pharmaceutical industry. It is important for investors to monitor these filings to understand the sentiment of company insiders.

Comparison to Industry Standards

• Form 4 filings are standard practice for publicly traded companies in the US, and this amendment is consistent with SEC regulations.
• The level of detail provided in the filing, including weighted average prices and price ranges, is typical for these types of disclosures.
• Other pharmaceutical companies such as Gilead Sciences and Moderna also have similar insider trading filings.

Stakeholder Impact

• The correction of the filing ensures that shareholders have accurate information about insider transactions.
• The director's share purchases may positively influence investor confidence.

Key Dates

Keywords

Atea Pharmaceuticals, insider trading, Form 4, stock acquisition, Franklin M. Berger, beneficial ownership, amendment